Skip to content
  • COMPANY
    • OVERVIEW
    • LEADERSHIP
    • BOARD
    • TIMELINE
  • OUR NETWORK
    • FOUNDERS
    • CONSULTANTS
    • INVESTORS
  • OUR SCIENCE
    • INTRODUCTION
    • Mode of Action
    • SCIENCE LIBRARY
  • PIPELINE
    • OVERVIEW
    • PMD-OPTION study
    • OMT-28
  • NEWS & EVENTS
  • TEAM & CAREERS
  • LEGAL NOTICE
  • DISCLAIMER
  • DATA PROTECTION
Back to NEWS

BIO-EUROPE 2025

Meet us at this outstanding partnering conference in Vienna, Austria, November 3–15

https://informaconnect.com/bioeurope

Post navigation

OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases
OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study
OMEICOS Therapeutics GmbH
Robert-Rössle-Strasse 10 (Building 79)
13125 Berlin, Germany
t +49 (0)30 9489 4810
f +49 (0)30 9489 4811
info@omeicos.com
OMEICOS Therapeutics, Inc.
c/o Remiges Biopharma Fund GP, Inc.
One Broadway, 14th Floor,
Cambridge, MA 02142, USA
info@omeicos.com
  • LEGAL NOTICE
  • DISCLAIMER
  • DATA PROTECTION
FOLLOW US
© 2025 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.